Photoactive platinum( ii ) β-diketonates as dual action anticancer agents
- 28 July 2016
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 45 (33) , 13234-13243
Abstract
Cyclometallated platinum( ii ) β-diketonates show significant photocytotoxicity in skin-keratinocyte HaCaT cells [IC 50 : ∼10 μM (visible light, 400–700 nm), ≥60 μM (dark)].Keywords
This publication has 80 references indexed in Scilit:
- The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) ProdrugsChemical Reviews, 2016
- A Potent Glucose–Platinum Conjugate Exploits Glucose Transporters and Preferentially Accumulates in Cancer CellsAngewandte Chemie International Edition, 2016
- Functionalization of Platinum Complexes for Biomedical ApplicationsAccounts of Chemical Research, 2015
- A New Approach to Reduce Toxicities and to Improve Bioavailabilities of Platinum-Containing Anti-Cancer NanodrugsScientific Reports, 2015
- Detouring of cisplatin to access mitochondrial genome for overcoming resistanceProceedings of the National Academy of Sciences, 2014
- Bispidine Analogues of Cisplatin, Carboplatin, and Oxaliplatin. Synthesis, Structures, and CytotoxicityInorganic Chemistry, 2014
- The Prodrug Platin‐A: Simultaneous Release of Cisplatin and AspirinAngewandte Chemie International Edition, 2014
- Synthetic Methods for the Preparation of Platinum Anticancer ComplexesChemical Reviews, 2013
- Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugsDalton Transactions, 2012
- Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetateProceedings of the National Academy of Sciences, 2009